Rigel Pharmaceuticals Inc
RIGL· Nasdaq
RIGLRigel Pharmaceuticals Inc
Released Aug 4, 2026, after the close
10-Q filed Aug 4, 2026, 35 days after period end · 0001034842-26-000052
| Metric | Q2 2026 | Q2 2025 | Q2 2024 | Q2 2023 |
|---|---|---|---|---|
| Revenue | $78.70M | $101.69M | $36.84M | $26.89M |
| Net Income | $17.29M | $59.61M | -$1.03M | -$6.60M |
| EPS Diluted |
Rigel Pharmaceuticals Inc · CIK 1034842 · Engraved from SEC EDGAR
| $0.88 |
| $3.28 |
| -$0.06 |
| -$0.38 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
